Abstract
The tolerability of cisplatin （CDDP） was retrospectively examined in 87 patients who received CDDP with concurrent chemoradiotherapy from May 2015 to July 2018. The CDDP doses were 80mg/m2 （80mg group） every 3 weeks until 2016 and 100mg/m2 （100mg group） every 3 weeks after January 2017. The 87 patients included 63 in the 80mg group and 24 in the 100mg group; 61.9％ and 70.8％ of patients received the full dose （240mg/m2 and 300mg/m2）, respectively. Grade 3 or worse adverse events were reported in 52.4％ and 70.8％ in the 80mg group and the 100mg group, respectively. The percentage of patients who received 200mg/m2 or more, which is the clinical recommended dose, was 68.3％ and 91.7％ of patients in the 80mg group and 100mg group, respectively. Chemoradiotherapy with CDDP 100mg/m2 would be a well-tolerated, high-dose treatment in Japan.
